API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SP-2577 (seclidemstat) is an oral LSD1 inhibitor, small molecule drug candidate. It is being evaluated in phase 1 /2 clinical trials for the treatment of Ewing sarcoma.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
SP-2577 (Seclidemstat) is an oral LSD1 inhibitor. It is being evaluated in phase 1 /2 clinical trials in combination with Azacitidine for the treatment of Hematologic Cancers.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
The Company intends to use the net proceeds for further development of its product candidates, including SP 2577 (seclidemstat), a potent and orally bioavailable inhibitor of lysine-specific demethylase 1.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP 2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 16, 2023
Details:
The Company intends to use the net proceeds for further development of its product candidates, including SP 2577 (seclidemstat), a potent and orally bioavailable inhibitor of lysine-specific demethylase 1.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP 2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 12, 2023
Details:
SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical trials for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical trials for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
The funding will support Salarius Pharmaceuticals operations and development of its drug candidate SP-2577 (seclidemstat) for the treatment of Ewing sarcoma.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Prevention and Research Institute of Texas
Deal Size: $16.1 million Upfront Cash: Undisclosed
Deal Type: Funding February 16, 2023
Details:
SP-2577 (seclidemstat) is a differentiated inhibitor of the LSD1 enzyme, a well-validated target for both hematological and solid tumors. SP-2577 inhibits LSD1's demethylation and scaffolding properties, representing a viable therapeutic option.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and certain additional sarcomas that share a similar biology, also referred to as Ewing-related or FET-rearranged sarcomas.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical studies for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression and is currently being studied in Phase 1/2 clinical studies for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oregon Health & Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Seclidemstat (SP-2577), a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: VolitionRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2022
Details:
Salarius intends to use the net proceeds from this offering for the continued clinical and pre-clinical development of its product candidates including SP-2577, and for other general corporate purposes.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 22, 2022
Details:
Seclidemstat is a novel, oral, reversible inhibitor of the lysine-specific histone demethylase 1 enzyme (LSD1), an enzyme that has been shown to play a key role in the development and progression of certain cancers.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2021
Details:
Salarius lead candidate, SP-2577 (seclidemstat) is currently advancing a Phase 1/2 dose-expansion clinical trial,used as a treatment for pediatric cancers, sarcomas, and other cancers.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
Seclidemstat (SP-2577), Salarius’ lead drug candidate, has a differentiated mechanism of action that gives it potent activity in sarcomas compared to another LSD1 inhibitor used in pediatric cancers, sarcomas and other cancers with limited treatment options.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nationwide Children’s Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
The grant will support development of lead drug candidate, Seclidemstat (SP-2577) is a novel, oral tablet, reversible inhibitor of lysine-specific histone demethylase 1 (LSD1), an enzyme that plays a key role in the development and progression of several cancers.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Prevention and Research Institute of Texas
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 28, 2021
Details:
Salarius is advancing a Phase 1/2 dose-expansion clinical trial evaluating seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide (TC) as a potential second- and third-line therapy for Ewing sarcoma, and for other FET-rearranged sarcomas.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Salarius' lead molecule, Seclidemstat, is a reversible LSD1 inhibitor. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a viable therapeutic option for patients who need it the most.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Pediatric Cancer Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
Details:
The funding supports development of seclidemstat, a reversible LSD1 inhibitor being studied in two clinical trials — one trial in relapsed/refractory Ewing sarcoma and a second trial in advanced solid tumors (AST).
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Prevention and Research Institute
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Funding January 13, 2021
Details:
The payments are part of an original non-dilutive grant of up to $18.7 million awarded in 2016 to support Salarius’ operations and development of its lead drug candidate, seclidemstat, for the treatment of Ewing sarcoma and other cancers.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Prevention and Research Institute of Texas
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding December 10, 2020
Details:
The European patent covers composition of matter and methods of use for seclidemstat, a potent reversible inhibitor of the LSD1 enzyme which is currently the subject of a Phase 1/2 clinical trial for Ewing sarcoma and a Phase 1/2 trial in advanced solid tumors.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Seclidemstat’s potential as a treatment for Ewing-related sarcomas is supported by pre-clinical data and early clinical data observations from the ongoing Phase 1/2 clinical trial of seclidemstat in patients with relapsed or refractory Ewing sarcoma.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
Seclidemstat is a reversible LSD1 inhibitor currently being studied in a Phase 1/2 clinical trial for Ewing sarcoma, a rare and deadly pediatric bone cancer for which there are no approved targeted treatments available.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Trial in Progress poster of the ongoing Phase 1/2 clinical trial of seclidemstat in patients with relapsed or refractory Ewing sarcoma will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20 Virtual).
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
The poster will provide an overview of the ongoing open-label, non-randomized dose-escalation/dose-expansion Phase 1/2 clinical trial of seclidemstat in patients with relapsed or refractory Ewing sarcoma.
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Seclidemstat is now in a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST).
Lead Product(s): Seclidemstat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2020